DIN 02171929 · ended Feb 12, 2025 · Disruption of the manufacture of the drug.
Showing 12 of 34 reports. All reports are on file with Health Canada.
What's happening
A manufacturer has told Health Canada it expects supply of Mesalazine to fall short of demand. Anticipated shortages sometimes resolve without patients noticing; this page updates as soon as the status changes.
Mesalazine is classified under “INTESTINALANTIINFLAMMATORY AGENTS” (ATC A07EC).
Recent changes
Jul 17, 2026
New report filed
Jul 17, 2026
New report filed
Jul 14, 2026
New report filed
Common questions
What is Mesalazine used for?
An anti-inflammatory medicine used to treat inflammatory bowel disease such as ulcerative colitis.
When will Mesalazine be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Mesalazine in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.